Company profile: Neumora
1.1 - Company Overview
Company description
- Provider of clinical-stage investigational therapies for brain diseases, conducting trials to evaluate new treatments. Portfolio includes navacaprant, an investigational oral Phase 3 medication for major depressive disorder that modulates dopamine and reward processing pathways, plus NMRA-NLRP3 and NMRA-GCASE programs for neurodegenerative diseases.
Products and services
- Navacaprant: A Phase 3 oral medication for Major Depressive Disorder that modulates dopamine and reward processing pathways to treat the disorder
- NMRA-GCASE: An enzyme-activating program focused on activating GCASE, under investigation for potential benefits in neurodegenerative diseases
- NMRA-NLRP3: A pathway-targeted program that targets the NLRP3 pathway and is under investigation for potential treatment of neurodegenerative diseases
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Neumora
Cerevance
HQ: United States
Website
- Description: Provider of therapeutics for CNS disorders, leveraging its NETSseq platform to identify novel targets. Pipeline includes CVN424, a first-in-class compound targeting a novel receptor with phase 2 efficacy in Parkinson’s disease; CVN766, a selective orexin 1 antagonist for psychiatric conditions focused on avoiding somnolence; and CVN293, a KCNK13 inhibitor under investigation for ALS and Alzheimer’s.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Cerevance company profile →
Sage Therapeutics
HQ: United States
Website
- Description: Provider of novel medicines for central nervous system (CNS) disorders, focused on debilitating and disabling conditions. Offers ZURZUVAE, an oral 14-day treatment for adults with postpartum depression, and ZULRESSO, an injectable for patients 15+ with postpartum depression. Pipeline includes SAGE-689 (acute GABA hypofunction), SAGE-421 (NMDA hypofunction), and SAGE-319 (GABA hypofunction).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Sage Therapeutics company profile →
Alector
HQ: United States
Website
- Description: Provider of neuroimmunology- and human genetics-informed antibody therapeutics for neurodegenerative diseases, with a pipeline including AL001 (targets progranulin for frontotemporal dementia with granulin mutation, Phase 3), AL002 (targets TREM2 to enhance microglia for Alzheimer's, Phase 2b), AL101 (increases progranulin for Alzheimer's/Parkinson's, Phase 2), and preclinical ABC candidates ADP027-ABC (GPNMB) and ADP050-ABC (GCase).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Alector company profile →
Javelin Pharmaceuticals
HQ: United States
Website
- Description: Provider of specialty pharmaceutical research, development, and commercialization of products for the pain management market primarily in the United States and Europe, focusing on treatments for various pain disorders ranging from acute and episodic moderate-to-severe pain.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Javelin Pharmaceuticals company profile →
NeuroPace
HQ: United States
Website
- Description: Provider of implantable neurostimulation devices for neurological disorders, featuring the FDA-approved RNS System for epilepsy to monitor brain activity, detect unusual patterns, and deliver responsive pulses to prevent seizures. Offers personalized neuromodulation based on patient brain activity, the nSight platform for remote data access, and clinical studies (NAUTILUS, RESPONSE, and other RNS System trials).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full NeuroPace company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Neumora
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Neumora
2.2 - Growth funds investing in similar companies to Neumora
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Neumora
4.2 - Public trading comparable groups for Neumora
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →